233
Views
5
CrossRef citations to date
0
Altmetric
Original Article

18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models

, , , , , & show all
Pages 763-771 | Received 22 Sep 2008, Accepted 27 May 2009, Published online: 22 Sep 2009
 

Abstract

Purpose: To determine the dependence of celecoxib on the tumour micro-environment in vitro and in vivo and to compare the use of 18F-Fluorodeoxyglucose (18F-FDG) and 18F- 3′-deoxy-3-fluorothymidine (18F-FLT) to measure tumour response.

Materials and methods: In vitro, colony assays were performed on a cyclo-oxygenase 2 (COX-2) negative (HCT116) and a COX-2 positive cell line (HCA7). Xenograft models of these cell lines were treated with celecoxib and/or radiotherapy. Micro Positron Emission Tomography (microPET) scans with 18F-FDG and 18F-FLT were performed at different time-points.

Results: In vitro, no radiosensitising effect was seen in either of the cell lines. In vivo results showed a significant effect of celecoxib in the COX-2 negative tumours (HCT116) (enhancement ratio 1.5, p = 0.02) while no significant effect was observed in the COX-2 positive model (HCA7). A good correlation between 18F-FDG and 18F-FLT uptake was seen in both tumour models (r = 0.48, p = 0.002; r = 0.41, p = 0.005). After irradiation, a decrease in the uptake of both tracers was observed in both tumour models, which was more pronounced in the combination group, confirming the growth delay data.

Conclusions: The contradicting in vitro and in vivo results suggest a major role of the tumour micro-environment. 18F-FLT seems a good alternative for 18F-FDG to follow tumour growth after radiation treatment.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.